Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). by El-Sheikh, A.A.K. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Functional Role of Arginine 375 in Transmembrane Helix 6
of Multidrug Resistance Protein 4 (MRP4/ABCC4)
Azza A. K. El-Sheikh, Jeroen J. M. W. van den Heuvel, Elmar Krieger,
Frans G. M. Russel, and Jan B. Koenderink
Department of Pharmacology and Toxicology (A.A.K.E., J.J.M.W.v.d.H., F.G.M.R., J.B.K.)
and Centre for Molecular and Biomolecular Informatics (E.K.), Radboud University Nijmegen Medical Centre,
Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
Received November 20, 2007; accepted July 8, 2008
ABSTRACT
Multidrug resistance protein (MRP) 4 transports a variety of
endogenous and xenobiotic organic anions. MRP4 is widely
expressed in the body and specifically localized to the renal
apical proximal tubule cell membrane, where it mediates the
excretion of these compounds into urine. To characterize the
MRP4 substrate-binding site, the amino acids Phe368, Phe369,
Glu374, Arg375, and Glu378 of transmembrane helix 6, and
Arg998 of helix 12, localized in the intracellular half of the central
pore, were mutated into the corresponding amino acids of
MRP1 and MRP2. Membrane vesicles isolated from human
embryonic kidney 293 cells overexpressing these mutants
showed significantly reduced methotrexate (MTX) and cGMP
transport activity compared with vesicles that expressed wild-
type MRP4. The only exception was substitution of Arg375 with
serine, which had no effect on cGMP transport but significantly
decreased the affinity of MTX. Substitution of the same amino
acid with a positively charged lysine returned the MTX affinity to
that of the wild type. Furthermore, MTX inhibition of MRP4-
mediated cGMP transport was noncompetitive, and the inhibi-
tion constant was increased by introduction of the R375S
mutation. A homology model of MRP4 showed that Arg375 and
Arg998 face right into the central aqueous pore of MRP4. We
conclude that positively charged amino acids in transmem-
brane helices 6 and 12 contribute to the MRP4 substrate-
binding pocket.
Proteins belonging to the ATP-binding cassette (ABC)
superfamily play a crucial role in human physiology, phar-
macology, and toxicology, as well as numerous pathological
conditions. To date, 48 human ABC transporter proteins
have been identified, including nine multidrug resistance
proteins (MRPs) belonging to the C subfamily (van de
Water et al., 2005). MRPs are not only important for the
tumor cell resistance they confer to chemotherapeutic
drugs but also for their endogenous expression in normal
human tissues. MRP4/ABCC4 is widely distributed in ep-
ithelial tissue and blood cells, and highest expression has
been found in kidney, lung, prostate, liver, tonsils, and
bladder (Borst et al., 2007). In most epithelial cells, MRP4
is located at the basolateral membrane, except for the
renal proximal tubular cell where it is expressed apically
(van Aubel et al., 2002). Structurally, the human MRP4
protein consists of 1325 amino acids composed of two
membrane-spanning domains each consisting of six trans-
membrane -helices (TM), with two cytosolic ATP-binding
domains. MRP4 mediates ATP-dependent transport of
various organic anions from the intracellular to the extra-
cellular side (Russel et al., 2008). Substrates include en-
dogenous compounds such as the cAMP and cGMP mono-
phosphate (van Aubel et al., 2002), folate (Chen et al.,
2002), and uric acid (Van Aubel et al., 2005), as well as
drugs such as the antiviral nucleoside monophosphate an-
alog 9-(2-phosphonylmethoxyethyl)adenine (Schuetz et al.,
1999) and the nucleobase analogs 6-mercaptopurine (Wiel-
inga et al., 2002) and methotrexate (MTX) (Chen et al.,
2002).
The mode by which MRPs transport their substrates has
still to be identified. Among the different MRPs, the struc-
ture-function relationship of MRP1 has been investigated
most extensively (Deeley et al., 2006). Several mutational
studies have shown that polar amino acids in transmem-
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brane helices 11 and 17 of MRP1 are involved in substrate
binding (Ito et al., 2001a,b; Zhang et al., 2001, 2006; Koike et
al., 2004). In a model, most of their side chains were found to
line the “pore” adjacent to the membrane cytosol interface. In
contrast with MRP1, limited knowledge regarding the amino
acids involved in substrate specificity of MRP2 (Ito et al.,
2001a) and MRP3 (Zhang et al., 2003b) is available.
To date, no attempt has been made to characterize the
MRP4 substrate-binding site(s). In the present study, we
investigated the role of Phe368, Phe369, Glu374, Arg375, and
Glu378 present in transmembrane helix 6 (TM11 in MRP1)
and Arg998 in transmembrane helix 12 (TM17 in MRP1) in
transport of cGMP and MTX. These amino acids are highly
conserved in MRP4 among different species (Chen and
Klaassen, 2004), but there is a large variety within the MRP
subfamily (Fig. 1) that might point to a specific mechanistic
importance of these amino acids. When they were substituted
by their analogs from MRP1/MRP2, most mutations abol-
ished MRP4 transport activity, except for Arg375 in which
cGMP transport was preserved, whereas the affinity for MTX
was reduced. We studied this mutation in more detail and
developed a homology model of MRP4 to explain the results.
Materials and Methods
Materials. [3,5,7-3H(N)]Methotrexate sodium salt (specific ac-
tivity, 51.5 Ci/mmol) and [8-3H]guanosine-3,5-cyclic phosphate
NH4 salt (specific activity, 7.7 Ci/mmol) were purchased from
Moravek Biochemicals (Brea, CA). The Bac-to-Bac Gateway system,
culture medium, and Alexa Fluor 680 goat anti-rabbit IgG secondary
antibody were purchased from Invitrogen (Breda, The Netherlands).
Methotrexate, guanosine 35-cyclic monophosphate, and GenElute
Plasmid Mini-Prep kit were purchased from Sigma (Zwijndrecht,
The Netherlands). Fetal bovine serum was purchased from MP Bio-
chemicals (Amsterdam, The Netherlands). Multiscreen HTS-HV
0.45-m, 96-well filters were obtained from Millipore (Etten-Leur,
The Netherlands). Protein concentrations were determined with an
assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands).
8-Azidoadenosine 5-triphosphate 2,3-biotin-long-chain-hydrazone
(8N3ATP-2,3-biotin-LC-hydrazone) was purchased from Affinity
Labeling Technologies (Nicholasville, KY), and streptavidin horse-
radish peroxidase conjugate was from GE Healthcare (Chalfont
St. Giles, UK).
Generation of HumanMRP4 Baculovirus. Full-length human
MRP4 cDNAwas generated as described previously (El-Sheikh et al.,
2007). Briefly, the Bac-to-Bac system, normally used for protein
production in insect cells, was modified for protein expression in
mammalian cells by introduction of the cytomegalovirus promoter
and Gateway destination elements (cassette that contains the chlor-
amphenicol resistance gene and the ccdB gene flanked by attR1 and
attR2 sites) in the pFastBacDual vector. In addition, the vesicular
stomatitis virus G protein cDNA was cloned behind the P10 pro-
moter of the pFastBacDual vector. The humanMRP4 was cloned into
the Gateway entry vector and transferred to the newly constructed
Bac-to-Bac vector with the gateway LR reaction. Baculoviruses were
produced as described in the Bac-to-Bac manual. As a negative
control, enhanced yellow fluorescent protein (EYFP) was also intro-
duced into the Baculovirus expression system (Invitrogen).
Site-Directed Mutagenesis. PCR was performed on a template
pENTR-MRP4 vector using two primers (forward and reverse) pro-
duced by Biolegio (Nijmegen, The Netherlands) bearing one or more
mismatched bases at the site of residues to be mutated. In this PCR
reaction, PfuUltra II fusion HS DNA polymerase with the supplied
reaction buffer, and dNTP mix (12.5 mM), each completed to 50-l
end volume, were used. PCR amplification consisted of initial dena-
turation at 94°C, followed by 20 cycles of denaturation at 94°C,
annealing at 58°C, and elongation at 72°C for 14 min. The PCR
product was cut by DpnI for 2 h at 37°C and finally transformed into
Fig. 2. Western blot analysis (A), 0.5 M [3H]MTX (B), and 1 M
[3H]cGMP (C) transport activity of wild-type, FF/L-, ERE/SSQ, and
FFERE/L-SSQ MRP4 transporter proteins. Top (A) represents a Western
blot of membrane vesicles isolated from HEK293 cells overexpressing
MRP4 or MRP4 mutants FF/L-, ERE/SSQ, and FFERE/L-SSQ as well as
a negative control detected by polyclonal anti-human MRP4 (representa-
tive of three). The MRP4 wild-type transport activity for [3H]MTX (950 
60 fmol/mg protein/min) and [3H]cGMP (114  7 fmol/mg protein/min)
was set at 100%.
Fig. 1. Alignment of amino acid sequence of TM6 (TM11) of MRP4 for
multiple species and human MRP1–6. The bold and underlined amino
acids have been mutated in this study.
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Escherichia coli DH5 cells. pENTR-MRP4 mutant plasmids were
isolated using the GenElute Plasmid Mini-Prep kit (Sigma) from
kanamycin-resistant colonies. All mutations were confirmed by se-
quencing of the full-length MRP4/ABCC4 DNA. Twelve mutants of
the human MRP4 were generated: FF/L- (F368L and F369-), ERE/
SSQ (E374S, R375S, and E378Q), FFERE/L-SSQ (F368L, F369-,
E374S, R375S, and E378Q), F368L, F369-, E374S, R375S, R375A,
R375K, R375E, E378Q, and R998A.
Transduction of MRP4 and Mutants Expression Vectors in
HEK293 Cells. HEK293 cells were cultured in 182-cm2 flasks until
40% confluent, after which the culture medium was removed and 3.5
ml of fresh medium and 1.5 ml of control EYFP, MRP4, or MRP4-
mutant baculovirus was added. The cells were incubated for 15 min
at 37°C, after which 20 ml of medium was added. After 24 h of
transduction, 5 mM sodium butyrate was added. Three days after
transduction, the cells were harvested.
Isolation of Membrane Vesicles and Protein Analysis. Cells
were harvested by centrifugation at 3000g for 30 min. The pellets
were resuspended in ice-cold homogenization buffer (0.5 mM sodium
phosphate and 0.1 mM EDTA, pH 7.4) supplemented with protease
inhibitors (100 M phenylmethylsulfonyl fluoride, 5 g/ml aprotinin,
5 g/ml leupeptin, 1 M pepstatin, and 1 M E-64) and shaken at
4°C for 60 min. Lysed cells were centrifuged at 4°C at 100,000g for 30
min, and the pellets were homogenized in ice-cold TS buffer (10 mM
Tris-HEPES and 250 mM sucrose, pH 7.4) using a tight-fitting
Dounce homogenizer for 30 strokes. After centrifugation at 500g at
4°C for 20 min, the supernatant was centrifuged at 4°C at 100,000g
for 60 min. The resulting pellet was resuspended in TS buffer and
passed through a 27-gauge needle 30 times. Protein concentration
was determined by Bio-Rad protein assay kit. Crude membrane
vesicles were dispensed in aliquots, frozen in liquid nitrogen, and
stored at 80°C until use.
Western Blotting. The membrane vesicle preparations (15 g of
protein) were solubilized in SDS-polyacrylamide gel electrophoresis
sample buffer and separated on SDS gels containing 7.5% acryl-
amide according to Laemmli (1970). Subsequently, they were blotted
on nitrocellulose membrane using the iBlot dry blotting system (In-
vitrogen). Polyclonal anti-human MRP4 rabbit serum antibody (van
Aubel et al., 2002) was used to detect human MRP4 and MRP4
mutants. The secondary antibody used was the fluorescent Alexa
Fluor 680 (Invitrogen). Signals were visualized with a fluorescent
method, using Odyssey infrared imaging system (Li-Cor Biosciences,
Lincoln, NE).
Vesicular Transport Assays. Uptake of [3H]MTX or [3H]cGMP
into membrane vesicles was performed using a rapid filtration tech-
nique. TSB buffer (TS buffer with 0.2 mg/ml bovine serum albumin)
supplemented with a mixture of 4 mM ATP and 10 mM MgCl2 was
added to the membrane vesicles in a final volume of 30 l. The
reaction was started when the mixture was incubated at 37°C. After
15 min, the reaction was stopped by placing samples on ice. After 1
min, 150 l of ice-cold TSB buffer was added to each reaction well.
Diluted samples were filtered by a Multiscreen HTS-Vacuum Man-
ifold filtration device (Millipore, Etten-Leur, The Netherlands)
through 0.45-m pore, 96-well Millipore filters that were prein-
cubated with TSB buffer. After adding 4 ml of scintillation fluid to
each filter and subsequent liquid scintillation counting, uptake of
[3H]MTX or [3H]cGMP into membrane vesicles was studied by mea-
suring radioactivity associated with the filters. In control experi-
ments, ATP was substituted with AMP. Net ATP-dependent trans-
port was calculated by subtracting values measured in the presence
of AMP from those measured in the presence of ATP. Each experi-
Fig. 3. Western blot analysis (A), 0.5 M [3H]MTX (B), and 1 M
[3H]cGMP (C) transport activity of wild-type, F368L, F369-, E374S,
R375S, and E378Q MRP4 transporter proteins. A, top, Western blot of
membrane vesicles isolated from HEK293 cells overexpressing MRP4 or
MRP4 mutants F368L, F369-, E374S, R375S, and E378Q, as well as
negative control detected by polyclonal anti-human MRP4 (representa-
tive of three). The MRP4 wild-type transport activity for [3H]MTX (970 
80 fmol/mg protein/min) and [3H]cGMP (106  7 fmol/mg protein/min)
was set at 100%.
Fig. 4. Concentration-dependent uptake of [3H]MTX and [3H]cGMP in
membrane vesicles expressing human MRP4 mutants. Control (Œ), wild-
type (f), F368L (F), F369- (), E374S (), R375S (E), and E378Q (x)
MRP4 membrane vesicles were incubated with [3H]MTX (top) or
[3H]cGMP (bottom) concentrations indicated in the figure. ATP-depen-
dent uptake was measured by subtracting uptake in the presence of AMP
from that measured in the presence of ATP. Mean values  S.E. of three
enzyme preparations are shown.
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ment was performed in triplicate using three different batches of
membrane vesicles.
Vesicular Inhibition Assays. To evaluate the inhibitory effects
of MTX on [3H]cGMP uptake in MRP4 and MRP4-R375S membrane
vesicles, the previously mentioned transport assay was performed
using 1, 10, and 100 M cGMP, in the absence or presence of MTX
concentrations ranging from 1 to 600 M. Net MRP4- or MRP4
mutant-dependent transport was calculated by subtracting back-
ground values measured in EYFP-transfected control vesicles.
Kinetic Analysis. All data were expressed as means  S.D.
Curve fitting of the resulting concentration-dependent transport
curves was performed by nonlinear regression analysis using Graph-
Pad Prism software, version 4.03 (GraphPad Software Inc., San
Diego, CA). Results of the inhibition assays were analyzed using
Dixon’s method, to estimate the inhibitory potency (Ki).
Immunoprecipitation and Photoaffinity Labeling.Wild-type
MRP4, negative (EYFP) control, and mutants (300 g of protein
vesicles) were incubated with 5 mMMgCl2 and 100 M 8-azido-ATP-
biotin (Scha¨fer et al., 2001) for 5 min on ice. The mixture was
photolinked using UV light for 10 min. Immunoprecipitation of the
photolinked sample was performed using MRP4 polyclonal antibody
(10 l/sample) (van Aubel et al., 2002) linked to protein A im-
mobilized on agarose [50% (w/v); KemEnTec, Copenhagen, Den-
mark] (30 l/sample). The immunoprecipitated protein was blotted
(see Western Blotting) and visualized with streptavidin horseradish
peroxidase.
Molecular Modeling of MRP4. The homology model of MRP4
was built with the YASARA molecular modeling program (Krieger et
al., 2002). A common problem when building models of membrane
proteins is the limited availability of experimental data. For MRP4,
the related X-ray structure of MsbA seemed to be incorrect and was
retracted, which left the structure of the bacterial ABC transporter
Sav1866 from Staphylococcus aureus solved at 3.0-Å resolution
(Dawson and Locher, 2006) as the only available template for the
transmembrane domain (PDB entry 2HYD). The cytosolic ATP-bind-
ing domain is, in contrast, well represented in the PDB. We therefore
selected the more closely related ATP-binding domain from human
MDR1 solved at 1.5-Å resolution (Ramaen et al., 2006), aligned it to
Sav1866 with YASARA’s MUSTANG module (Konagurthu et al.,
2006), and then fused it with the Sav1866 transmembrane domain to
create a hybrid-template. The alignment of the MRP4 sequence
against this template was created with the T-Coffee multiple align-
ment algorithm (Notredame et al., 2000), using an additional 48
intermediate sequences to guide the alignment. These 48 sequences
were randomly selected from Swissprot/TrEMBL, with the require-
ment that their transmembrane domains be closer to both the tem-
plate and MRP4, than the template is to MRP4. The resulting align-
ment was manually tuned to account for single residue insertions
and deletions in the membrane helices, which contain several Gly/
Pro-mediated deviations from ideality in the Sav1866 template.
Loops were modeled by scanning a nonredundant subset of the PDB
(8000 structures) for fragments with matching anchor points, a
minimal number of bumps, and maximal sequence similarity. Side
chains were added with YASARA’s implementation of SCWRL (Ca-
nutescu et al., 2003), and then the model was subjected to an energy
minimization with the YAMBER force field as described previously
(Krieger et al., 2004, 2006). Since no membrane was present during
this minimization, the backbone of residues copied from the template
was kept fixed. Validation of the model with WHAT_CHECK (Hooft
et al., 1996) yielded an average quality Z-score of 2.2, which is
Fig. 5. Dixon plot showing the MTX inhibition of cGMP transport by
human MRP4 and mutant R375S. Membrane vesicles were incubated
with 1 M (open circles), 10 M (closed triangles), or 100 M (open
squares) [3H]cGMP in the presence or absence of MTX concentrations
ranging from 1 to 600 M. Specific uptake of MRP4 (top) and mutant
R375S (bottom) was determined after subtraction of the negative control.
The inhibition constant (Ki) can be estimated from the intersection point
of the three lines with the x-axis. Mean values  S.E. of three enzyme
preparations are shown.
Fig. 6. Western blot analysis (A), 0.5 M [3H]MTX (B), and 1 M
[3H]cGMP (C) transport activity of wild-type, R375A, R375K, R375E, and
R998A MRP4 transporter proteins. A, top, Western blot of membrane
vesicles isolated from HEK293 cells overexpressing MRP4 or MRP4 mu-
tants R375A, R375K, R375E, and R998A, as well as negative control
detected by polyclonal anti-human MRP4 (representative of three). The
MRP4 wild-type transport activity for [3H]MTX (980  20 fmol/mg pro-
tein/min) and [3H]cGMP (125 13 fmol/mg protein/min) was set at 100%.
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better than the template (2.9). A PDB file of the model and the
alignment is available from us upon request.
Results
Three mutants of human MRP4 were generated and ex-
pressed in HEK293 cells. In mutant FF/L-, Phe368 and Phe369
in TM6 were replaced by their analogs in MRP1/MRP2 (Leu
and nothing, respectively). In the second mutant, ERE/SSQ,
Glu374, Arg375, and Glu378 in TM6 were also replaced by their
analogs in MRP1/MRP2 (Ser, Ser, and Gln, respectively). The
final mutant FFERE/L-SSQ was a combination of mutant
FF/L- and mutant ERE/SSQ. Western blot analysis of mem-
brane vesicles prepared from HEK293 cells overexpressing
wild-type MRP4, and the three mutants showed comparable
expression levels (Fig. 2A). Often two bands are visible, of
which the mutual ratio varies in different preparations.
N-Glycosidase F treatment showed that the most intense
band that runs at 170 kDa is the glycosylated MRP4 protein,
and the band that runs at 140 kDa is the unglycosylated
MRP4 band (data not shown). MRP4-mediated ATP-depen-
dent transport of 0.5 M [3H]MTX or 1 M [3H]cGMP was
950  60 and 114  7 pmol/mg protein/min, respectively. In
Fig. 2B, the transport activity of the mutants is compared
with that of the wild type. Transport of both substrates in all
mutants was significantly decreased compared with that of
the wild-type transporter. Moreover, the transport activity
levels were comparable with that of the negative control.
To investigate the substitution of the amino acids of the
previous mutants in more detail, we constructed the single
mutants F368L, F369-, E374S, R375S, and E378Q. Again,
the membrane vesicles of all mutants showed expression
levels comparable with wild-type MRP4 (Fig. 3A). The trans-
port activity of both [3H]MTX and [3H]cGMP (0.5 and 1 M,
respectively) was significantly reduced in mutants F368L,
F369-, E374S, and E378Q compared with wild-type MRP4
(Fig. 3). Interestingly, cGMP transport activity of mutant
R375S was 98  2% of wild type, whereas its MTX transport
activity was only 55  2%.
Next, we determined the transport activity of the mutants
and wild-type transporter at different substrate concentra-
tions. Figure 4 shows the Michaelis-Menten plot for MTX and
cGMP. Mutants F368L, F369-, E374S, and E378Q showed
transport activity levels that were comparable with that of
the negative control at all concentrations tested for bothMTX
and cGMP. The maximum transport rate (Vmax) values for
the wild-type and R375S mutant were 280  60 and 270 
120 pmol/mg protein/min for MTX and 370  30 and 270 
70 pmol/mg protein/min for cGMP, respectively. The appar-
ent affinity (Km) values of wild-type MRP4 and mutant
R375S were 230  90 and 720  320 M for MTX and 610 
70 and 610 80 M for cGMP, respectively. The Km value for
cGMP was not influenced by substitution of Arg375 with Ser,
whereas it was increased 3-fold for MTX.
To test the interaction of MTX and cGMP in more detail,
we analyzed the possible inhibitory effect of MTX on
[3H]cGMP uptake for wild-type and R375S mutant MRP4. A
Dixon plot of net cGMP transport by wild type and R375S in
the absence or presence of increasing MTX concentrations
was constructed and analyzed by linear regression (Fig. 5).
Remarkably, the intersection of the three lines representing
MTX inhibition curves at different cGMP concentrations was
at the x-axis for both wild type and R375S mutant, indicating
a noncompetitive inhibitory effect. The inhibition constant
value (intersection with the x-axis), Ki, for wild-type MRP4
was 164  4 M, compared with 470  70 M for mutant
R375S.
At this point, however, it was not clear whether this effect
was due to the introduction of a polar serine or to the deletion
Fig. 7. Concentration-dependent uptake of [3H]MTX and [3H]cGMP in
membrane vesicles expressing human MRP4 mutants. Control (Œ), wild-
type (f), R375A (F), R375K (E), R375E (), and R998A (x) MRP4 mem-
brane vesicles were incubated with [3H]MTX (top) or [3H]cGMP (bottom)
concentrations indicated in the figure. ATP-dependent uptake was mea-
sured by subtracting uptake in the presence of AMP from that measured
in the presence of ATP. Mean values S.E. of three enzyme preparations
are shown.
Fig. 8.Western blot of immunoprecipitated 8-azido-ATP-biotin photolabeled wild-type and mutant transporter proteins. We labeled 300 g of protein
vesicles with 100 M 8-azido-ATP-biotin, and the MRP4 proteins were immunoprecipitated with MRP4 polyclonal antibody linked to agarose protein
A beads. The immunoprecipitated protein was blotted and visualized with streptavidin horseradish peroxidase. The addition of 5 mM ATP prevented
photolabeling (data not shown).
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of the positively charged arginine. In the next experiment, we
replaced arginine with alanine, lysine, and glutamic acid.
Furthermore, we substituted the arginine present in TM12
for alanine. Figure 6A shows an equal level of protein expres-
sion of wild type as well as R375A, R375K, R375E, and
R988A mutants. The MTX and cGMP transport activity of
the wild-type and mutants was measured and shown in Fig.
6B. Mutating the Arg375 residue into alanine or glutamic acid
significantly decreased the transport activity for both MTX
and cGMP, whereas mutating it into lysine retained the
transport activity (96  12% for MTX and 97  16% for
cGMP). In addition, the transport levels of R988A showed no
significant difference from the negative control.
To determine the Km values of the different mutants for
MTX and cGMP, concentration-dependent transport experi-
ments were performed (Fig. 7). The transport activities of
R375A, R375E, and R988A for MTX and cGMP did not differ
from that of the negative control. The Vmax values for MTX
were 250  20 and 190  10 pmol/mg protein/min and those
for cGMP were 420  10 and 420  20 pmol/mg protein/min
for wild type and R375S mutant, respectively. The Km values
of wild-type MRP4 and R375K were 230  90 and 250  20
M for MTX and 610  70 and 640  60 M for cGMP,
respectively. Thus, R375K retained substrate affinity compa-
rable with the wild type for both MTX and cGMP.
To determine whether the MRP4 mutants showed normal
ATP binding, 8-azido-ATP-biotin photolabeling of mutants
was compared with that of wild type and negative control
(Fig. 8). The vesicles of MRP4 wild type and mutants showed
increased 8-azido-ATP-biotin binding compared with the
negative control. In all mutant preparations, the 8-azido-
ATP-biotin binding was comparable with that of the wild
type. Moreover, the binding of 8-azido-ATP-biotin was almost
completely diminished when ATP was added.
To link the functional consequences of the mutations back
to their structural basis, we built a homology model of MRP4
using the known X-ray structures of the bacterial ABC trans-
porter Sav1866 from S. aureus (Dawson and Locher, 2006)
and the ATP-binding domain of human P-glycoprotein/MDR1
as templates (Ramaen et al., 2006) (Fig. 9A). Sav1866 forms
a dimer, whereas MRP4 encodes both copies in a single
sequence. The predicted location of the mutated residues is
shown in Fig. 9B. Based on this model, one can postulate that
Arg375 and Arg998 face right into the pore and are thus very
likely to interact directly with MTX and cGMP.
Discussion
To characterize the MRP4 substrate-binding site, we in-
vestigated the influence of Phe368, Phe369, Glu374, Arg375,
and Glu378 of transmembrane helix 6 and the influence of
Arg998 of helix 12 on cGMP and MTX transport. These amino
acids were substituted by their corresponding amino acids of
MRP1 andMRP2. Most mutations abolishedMRP4 transport
activity. The only exception was substitution of Arg375 with
serine, which had no effect on cGMP transport, but signifi-
cantly decreased the affinity for MTX. Substitution of the
same amino acid with a positively charged lysine returned
the MTX affinity to that of the wild type. A homology model
of MRP4 confirmed the crucial role of Arg375 and showed that
it faced right into the central pore.
Wild-type MRP4 and all mutants were equally expressed
in vesicles isolated from transduced HEK293 cells. Neverthe-
less, several MRP4 mutants (FF/L-, ERE/SSQ, FFERE/L-
SSQ, F368L, F369-, E374S, R375A, R375E, E378Q, and
R998A) showed significantly diminished transport activity of
either MTX or cGMP compared with that of wild-type MRP4.
This indicates that Phe368, Phe369, Glu374, Arg375, and
Glu378, present in TM6, and Arg998, present in TM12, might
comprise an important part of MRP4 substrate-binding site.
Indeed, studies with LmrA, a bacterial ATP-dependent mul-
tidrug transporter, show that TM3, TM5, and TM6 (also
TM9, TM11, and TM12) are involved in substrate binding
(Ecker et al., 2004). These TMs have one face of the helix
exposed to the pore, which forms a pathway for substrates
through the membrane. Experimental evidence has shown
Fig. 9. Homology model of human MRP4 (A). The first half of the protein containing transmembrane helices 1 to 6 and the first ATP-binding domain
are colored with a gradient from blue over orange to cyan. The second half of the protein (corresponding to the second monomer in the dimeric Sav1866
modeling template) is shown in gray. A 180° rotation around the vertical axis would yield an almost identical picture of helices 7 to 12 and the second
ATP-binding domain. B, close-up of the channel formed by the 12 transmembrane helices, looking from the inside to the extracellular side. The
mutants described in this work are indicated. Graphics created with www.YASARA.org.
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that conformational changes of the nucleotide-binding do-
mains (NBD) of P-glycoprotein/MDR1, leads to reorientation
of the TM helices (Loo et al., 2007). TM6 is connected to
NBD1 and changes in the position or orientation of TM6
resulting from mutations, may cause a conformational or
positional change in NBD1 leading to diminished binding of
ATP and transport activity (Zhang et al., 2004). We tested
whether the mutants were able to bind 8-azido-ATP-biotin
and observed no difference in binding between MRP4 and the
mutants.
All the amino acids mutated in the present study are
highly conserved in MRP4 among different species (Chen and
Klaassen, 2004). There is, however, a big difference within
the MRP subfamily that might point to a specific mechanistic
importance of these amino acids. The two phenylalanines at
position 368 and 369 in MRP4 are unique and absent in other
MRPs. Replacement of these two amino acids by a single
leucine (their counterpart in MRP1, -2, -3, and -5) resulted in
the lack of MTX and cGMP transport. The Phe369, predicted
to face outside the central pore and attach helix 6 to helix 3,
most likely has a role in maintaining the structural integrity
of the transporter. Phe368 faces into the pore and could me-
diate stacking interactions with the planar rings of cGMP
and MTX. The negatively charged glutamic acid residues at
position 374 and 378 of MRP4 correspond to a serine and
glutamine, respectively, in MRP1, -2, and -6. The replace-
ment of these two MRP4 amino acids by serine and glu-
tamine also resulted in the lack of MTX and cGMP transport.
Zhang et al. (2004) showed that replacement of MRP1 Ser604
(corresponding to E374S in MRP4) with alanine selectively
increased 17-estradiol 17-(-D-glucuronide) transport. In
the model, Glu374 and Glu378 form salt bridges with Arg317
and Arg262, which points toward a role in maintaining the
structural integrity of the transporter.
In this study, we showed that the positively charged argi-
nine residue at position 375 is important for MRP4-mediated
MTX but not cGMP transport. The importance of positively
charged amino acids to the binding and transport function-
ality was indicated previously for MRP1 (Zhang et al.,
2003a). Deletion of the hydroxyl group of MRP1 residue 605
(S605A), corresponding to R375A in MRP4, decreased resis-
tance to vincristine, etoposide (VP-16), and doxorubicin
(Zhang et al., 2004). Moreover, the Q359K/T360K mutation
(corresponding to MRP4 Glu374 and Arg375) in the cystic
fibrosis transmembrane conductance regulator protein causes
cystic fibrosis (Quint et al., 2005).
In the present study, substitution of MRP4 Arg375 with
serine resulted in a lower affinity for MTX, but the affinity
for cGMP did not change (Table 1). Furthermore, the MTX
inhibition constant for cGMP transport by mutant R375S
was significantly lower than that of the wild type. When the
arginine at position 375 of MRP4 was substituted with ly-
sine, another positively charged amino acid, MTX and cGMP
transport activities were similar to that of the MRP4 wild
type. For MTX affinity, the positive charge of MRP4 residue
375 is critical. When this charge is removed (R375S), the
MTX affinity decreases or transport activity is absent (R375A
and R375E). This positive charge is less important for cGMP
transport, because in the presence of a hydroxyl group
(R375S), the transport properties seem unchanged. As soon
as this hydroxyl group is removed (R375A) or replaced with a
(negatively charged) acidic group (R375E), transport of
cGMP is absent. Our observation that the R375S mutation
has a larger effect on MTX transport could be explained by
the fact that MTX contains two negative charges that need to
be compensated, whereas cGMP only has one. Regardless,
our results show that lysine is equally well suited as arginine
to mediate this interaction.
Photolabeling and mutational studies aimed at predicting
regions of MRP1 protein that contribute to the substrate-
binding sites have outlined the possible role of TM17 (Daoud
et al., 2001; Deeley et al., 2006), which corresponds to TM12
in MRP4. In the present work, we mutated Arg998 located at
MRP4 TM12 into alanine. Substitution of this positively
charged amino acid resulted in near abolition of transport
activity for either MTX or cGMP. It was reported that the
corresponding amino acid Arg1257 in MRP2 showed de-
creased transport activity of glutathione-methylfluorescein
when substituted with alanine (Ryu et al., 2000). Moreover,
alanine substitution of Arg1249 in MRP1 (also corresponding
to R998A) impaired MRP1-mediated LTC4 transport and
reduced vincristine resistance (Ren et al., 2002). This indi-
cates the participation of TM12 to the MRP4 binding pocket
and emphasizes the importance of positively charged amino
acids for MRP4 transport activity. Although mutagenesis
studies confirm the functional requirement of a positive
charge at Arg375, this has not been confirmed for Arg998.
Glutamic acid (R998E) and lysine (R998K) mutants would be
needed to strengthen this conclusion.
Complex substrate-transporter interactions have been de-
scribed previously for ABC transporters such as P-glycopro-
tein/MDR1 (Martin et al., 2000), MRP1 (Leslie et al., 2001),
MRP2 (Zelcer et al., 2003), and MRP4 (Van Aubel et al.,
2005). These complexities were attributed to multiple allo-
steric-binding sites. Here, we encountered similar complex
transport inhibition patterns. Mutant R375S and wild-type
MRP4 possessed similar affinities for cGMP, but the MTX
affinity of this mutant was nearly 3-fold lower than that of
the wild type. This implicates that these two MRP4 sub-
strates do not share the same substrate-binding site. This
was also implied by the noncompetitive inhibitory effect of
MTX on MRP4-mediated cGMP transport. Therefore, we pro-
pose that MRP4 can bind two substrates at different regions
within the aqueous cavity involving overlapping amino acids.
This could partly explain the complex inhibitory and stimu-
latory kinetics that we encountered in previous studies (Van
Aubel et al., 2005; El-Sheikh et al., 2007). Our data are
indicative; they are nonetheless based on a homology model
and mutagenesis studies, both of which contain certain ex-
perimental caveats.
We conclude that amino acids in the transmembrane heli-
ces 6 and 12 may comprise a crucial part of the MRP4
TABLE 1
Transporter kinetic values and inhibition constants
MTX cGMP
Km Vmax Km Vmax Ki
M pmol/mg/min M pmol/mg/min M
Data from Figs. 3 and 4
MRP4 230  90 280  60 610  70 370  30 164  4
R375S 720  320 270  120 610  80 270  70 470  70
Data from Fig. 4
MRP4 230  90 250  20 610  70 420  10
R375K 250  20 190  10 640  60 420  20
970 El-Sheikh et al.
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substrate-binding site. The importance of a positive charge at
residue 375 seems evident for MTX transport, but not for
cGMP. This residue, which is predicted to be in the aqueous
cavity of the inner leaflet of the membrane, clearly affects
substrate specificity. Furthermore, a noncompetitive inhibi-
tion between MTX and cGMP has been revealed, indicating
separate MRP4 substrate-binding sites.
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